Clinical trial No longer in our active list Phase2; Phase3 Interventional Ages 18 to 75

Evaluating BHV-7000 for treating refractory focal onset epilepsy in adults

Official title: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy

Run by Biohaven Pharmaceuticals, Inc. · NCT06132893 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new treatment called BHV-7000 to see if it can help adults with difficult-to-treat focal onset epilepsy reduce their seizures.

More Focal Epilepsy trials Research outlook What's coming for Epilepsy: the next 6 months to 5 years

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment390 (estimated)
SponsorBiohaven Pharmaceuticals, Inc.
Industry-sponsored
Locations124 sites (Phoenix, Arizona and 123 other locations)
Trial IDNCT06132893 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 75 with a diagnosis of refractory focal onset epilepsy who have failed multiple anti-seizure medications.

Probably not a fit

Patients with a history of status epilepticus or those who do not meet the criteria for refractory epilepsy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness and safety of BHV-7000 in adults suffering from refractory focal onset epilepsy. Participants will be administered either BHV-7000 or a placebo, with the goal of determining if this new treatment can help reduce seizure frequency. The study will include adults aged 18 to 75 who have a diagnosis of focal onset epilepsy and have not responded adequately to previous anti-seizure medications. Participants will be required to maintain accurate seizure diaries throughout the study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve seizure control for patients with refractory focal onset epilepsy.

How similar studies have gone: Other studies have explored treatments for refractory epilepsy, but the specific approach with BHV-7000 is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

1. Male and Female participants 18 to 75 years of age at time of consent.
2. Diagnosis of Focal Onset Epilepsy at least 1 year prior to screening visit defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.

   a. Focal seizures i. Focal aware seizures with clinically observable signs and/or symptoms ii. Focal impaired awareness seizures iii. Focal to bilateral tonic-clonic seizures
3. Subject meets the 2009 ILAE definition of drug resistant epilepsy, failure of adequate trials of two tolerated and appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
4. Ability to keep accurate seizure diaries
5. Current treatment with at least 1 and up to 3 ASMs and 4 epilepsy treatments in total

Key Exclusion Criteria:

1. History of status epilepticus (convulsive status epilepticus for \> 5 minutes or focal status epilepticus with impaired consciousness for \> 10 minutes) within the last 6 months prior to screening visit that is not consistent with the subject's habitual seizure.
2. History of repetitive/cluster seizures (where individual seizures cannot be counted) within the last 6 months prior to screening visit and during observation phase.
3. Resection neurosurgery for seizures \<4 months prior to the screening visit.
4. Radiosurgery performed \<2 years prior to the screening visit.
5. Subjects with only focal aware nonmotor seizures which involve subjective sensory or psychic phenomena only, without impairment of consciousness or awareness (formally called simple partial seizures), with or without ictal EEG correlation with clinical symptoms.
6. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator

Where it's running

  • Barrow Neurological Institute
    Phoenix, Arizona, United States
    Recruiting
  • Center for Neurosciences
    Tucson, Arizona, United States
    Recruiting
  • Clinical Trials, Inc.
    Little Rock, Arkansas, United States
    Recruiting
  • University of California San Diego
    La Jolla, California, United States
    Recruiting
  • University of California, Los Angeles
    Los Angeles, California, United States
    Recruiting
  • Stanford Health Care
    Palo Alto, California, United States
    Recruiting
Show 44 more locations
  • Profound Research LLC
    Pasadena, California, United States
    Recruiting
  • University of Colorado Anschultz Medical Campus
    Aurora, Colorado, United States
    Recruiting
  • Yale School of Medicine - Yale-New Haven Hospital
    New Haven, Connecticut, United States
    Recruiting
  • EZR Research LLC
    Boca Raton, Florida, United States
    Recruiting
  • Nova Clinical Research, LLC
    Bradenton, Florida, United States
    Recruiting
  • University of Florida (Jacksonville)
    Jacksonville, Florida, United States
    Recruiting
  • University of Miami
    Miami, Florida, United States
    Recruiting
  • Medsol Clinical Research Center
    Port Charlotte, Florida, United States
    Recruiting
  • Santos Research Center
    Tampa, Florida, United States
    Recruiting
  • Encore Medical Research of Weston LLC.
    Weston, Florida, United States
    Recruiting
  • Augusta University
    Augusta, Georgia, United States
    Recruiting
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii, United States
    Recruiting
  • Consultants in Epilepsy & Neurology, PLLC
    Boise, Idaho, United States
    Recruiting
  • Northwestern University
    Chicago, Illinois, United States
    Recruiting
  • Revive Research Institute, Inc.
    Elgin, Illinois, United States
    Recruiting
  • Bluegrass Epilepsy Research
    Lexington, Kentucky, United States
    Recruiting
  • Maesc
    Bethesda, Maryland, United States
    Recruiting
  • Minnesota Epilepsy Group, P.A.
    Roseville, Minnesota, United States
    Recruiting
  • Washington University School of Medicine
    St Louis, Missouri, United States
    Recruiting
  • Nereg
    Hackensack, New Jersey, United States
    Recruiting
  • Inst of Neurology
    Livingston, New Jersey, United States
    Recruiting
  • Dent Neurosciences Research Center
    Amherst, New York, United States
    Recruiting
  • Bchp
    Hawthorne, New York, United States
    Recruiting
  • Northwell Health
    New York, New York, United States
    Recruiting
  • Stony Brook Medicine
    Stony Brook, New York, United States
    Recruiting
  • Five Towns Neuroscience Research
    Woodmere, New York, United States
    Recruiting
  • Wake Forest Baptist
    Winston-Salem, North Carolina, United States
    Recruiting
  • NeuroScience Research Center
    Canton, Ohio, United States
    Recruiting
  • University of Cincinnati
    Cincinnati, Ohio, United States
    Recruiting
  • Osu
    Columbus, Ohio, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Thomas Jefferson University
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Upmc
    Pittsburgh, Pennsylvania, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
    Recruiting
  • Neurology Consultants of Dallas, PA
    Dallas, Texas, United States
    Recruiting
  • UT Health San Antonio
    San Antonio, Texas, United States
    Recruiting
  • Road Runner Research, Ltd
    San Antonio, Texas, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah, United States
    Recruiting
  • University of Virginia
    Charlottesville, Virginia, United States
    Recruiting
  • Henrico Doctors Neurology Associates, LLC
    Richmond, Virginia, United States
    Recruiting
  • Carilion Clinic
    Roanoke, Virginia, United States
    Recruiting
  • STAT Research S.A.
    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Recruiting
  • Hospital General de Agudos Dr. José María Ramos Mejia
    Balvanera, Ciudad Autónoma de BuenosAires, Argentina
    Recruiting
  • Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno CEMIC-Elías Galván 4102
    Buenos Aires, Ciudad Autónoma de BuenosAires, Argentina
    Recruiting

+74 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • High-density flexible microneuroelectrode mapping to guide epilepsy surgery

    This study tests whether using high-density flexible microelectrocorticography during surgery helps guide the resection of the epileptogenic zone in people with drug-resistant focal epilepsy.

    Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07656857

  • RAP-219 for adults with focal seizures

    This study tests whether RAP-219 can reduce how often focal seizures happen in adults with focal epilepsy, compared with a placebo.

    Recruiting at 14 sites Phase 3 Rapport Therapeutics Inc. · Huntsville, Alabama and 13 other locations · NCT07594119

  • Spatial scene memory testing for people with temporal lobe epilepsy having surgery

    This project tests whether a virtual tour memory task combined with brain recordings can show how adults with temporal lobe epilepsy recognize and recall places.

    Recruiting at 2 sites University of California, Davis · Sacramento, California and 1 other locations · NCT07580183

  • RAP-219 in adults with focal seizures

    This study tests whether RAP-219 can safely reduce the number of focal seizures in adults with focal epilepsy compared with placebo.

    Recruiting at 24 sites Phase 3 Rapport Therapeutics Inc. · Birmingham, Alabama and 23 other locations · NCT07563881

  • Probenecid for cluster seizures during presurgical epilepsy monitoring

    This trial tests whether probenecid can help control clusters of seizures in people with focal epilepsy during presurgical video-EEG monitoring.

    Recruiting Phase 2 Fondation Ophtalmologique Adolphe de Rothschild · Paris and 1 other locations · NCT07318870

  • Long-term daily CB03-154 treatment for focal epilepsy

    This extension will try once-daily CB03-154 (up to 20 mg) in people with focal epilepsy who completed the prior Phase 2 study to see if it is safe, tolerated, and helps control seizures over up to two years.

    Recruiting Phase 2 Shanghai Zhimeng Biopharma, Inc. · Melbourne, Victoria · NCT07238868

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.